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Abstract
Background: Induction chemotherapy is a common therapeutic option for patients with locoregionally-advanced head and
neck cancer (HNC), but it remains unclear which patients will benefit. In this study, we searched for biomarkers predicting
the response of patients with locoregionally-advanced HNC to induction chemotherapy by evaluating the expression
pattern of DNA repair proteins.
Methods: Expression of a panel of DNA-repair proteins in formalin-fixed paraffin embedded specimens from a cohort of 37
HNC patients undergoing platinum-based induction chemotherapy prior to definitive chemoradiation were analyzed using
quantitative immunohistochemistry.
Results: We found that XPF (an ERCC1 binding partner) and phospho-MAPKAP Kinase 2 (pMK2) are novel biomarkers for
HNSCC patients undergoing platinum-based induction chemotherapy. Low XPF expression in HNSCC patients is associated
with better response to induction chemoradiotherapy, while high XPF expression correlates with a worse response
(p = 0.02). Furthermore, low pMK2 expression was found to correlate significantly with overall survival after induction plus
chemoradiation therapy (p = 0.01), suggesting that pMK2 may relate to chemoradiation therapy.
Conclusions: We identified XPF and pMK2 as novel DNA-repair biomarkers for locoregionally-advanced HNC patients
undergoing platinum-based induction chemotherapy prior to definitive chemoradiation. Our study provides insights for the
use of DNA repair biomarkers in personalized diagnostics strategies. Further validation in a larger cohort is indicated.
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Introduction
Head and neck squamous cell carcinoma (HNSCC) is the 6th
most common malignant neoplasm worldwide and accounts for
45.000 new cases in the US every year [1,2]. For practical
purposes, head and neck cancer is divided into three clinical
stages: early, locoregionally-advanced, and metastatic or recurrent.
Treatment approaches can vary depending on the disease stage.
The vast majority of patients (,60%) presenting with locoregion-
ally-advanced disease require aggressive multimodality therapy.
Reported long-term survival rates ranges between 50–70% [3,4].
Induction or neoadjuvant chemotherapy is increasingly used prior
to definitive local therapy (i.e. surgery/chemoradiotherapy/
radiation) and FDA approved for this indication. Induction
chemotherapy is associated with high response rates, symptomatic
relief, and a reduction in distant metastatic failures. Moreover,
several groups including ours have reported a clear association
between response to induction chemotherapy and improved
overall survival [5–7]. Despite a high degree of activity, a recent
phase III study failed to show benefit of adding induction
chemotherapy to chemoradiotherapy in an unselected patient
population [8]. Subgroup analysis suggested potential benefit in
certain high-risk populations, but in the absence of a suitable
biomarker validation of hypotheses will be difficult and expensive.
A meta-analysis also confirmed a small survival advantage with
induction chemotherapy despite heterogeneity of the included
therapies [9]. Unfortunately, there is currently no validated
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method to predict which patients will benefit from this therapy and
it remains unclear how to select patients for this potentially
beneficial as well as potentially toxic therapy. Biomarkers could
help to improve patient selection in the future.
DNA repair proteins play an essential role in maintaining
genome stability and have been implicated in tumorigenesis.
Patients with chromosomal instability syndromes such as Fanconi
anemia (FA), ataxia telangiectasia (AT), Bloom’s syndrome or
Werner syndrome show defects in DNA repair and an associated
increased risk and poor prognosis for cancer including head and
neck cancers [10–17]. Cancer cells exhibit genomic instability and
are often defective in one of six major DNA repair pathways
namely: base excision repair (BER), nucleotide excision repair
(NER), mismatch repair (MMR), homologous recombination
(HR), nonhomologous endjoining (NHEJ), and translesion DNA
synthesis (TLS). Chemotherapy and most chemotherapeutic
agents damage DNA and lack of adequate repair induces tumor
cell death.
Therefore, it is crucial to identify DNA repair biomarkers that
can predict which patients benefit from induction chemotherapy
in locoregionally-advanced head and neck cancer.
Previous reports suggest that ERCC1 is a potential biomarker
for platinum-based therapy [18–20]. The ERCC1 protein binds to
XPF to form a heterodimer, which is a DNA specific endonuclease
structure that stabilizes one another in vivo and is responsible for
the 59 incision during nucleotide excision repair [21]. Levels of
ERCC1 are significantly reduced in XPF deficient cells and vice
versa [22]. This biomarker has not been adopted for HNSCC in
part due to controversy surrounding the specificity of the
employed antibody [23,24]. Other studies found, that resistance
towards platinum-based chemotherapy correlates with protein or
mRNA levels of ERCC1 and XPF [21,25,26].
In this study, we investigated a panel of DNA repair proteins in
five major DNA repair pathways using immunohistochemistry
(IHC) and a digital pathology platform to evaluate whether the
expression pattern of DNA repair proteins at the biopsy stage can
predict tumor response in patients with locoregionally-advanced
HNSCC undergoing induction chemotherapy prior to definitive
chemoradiation. Our study shows that XPF is highly variable
among head and neck cancers with a wide dynamic range: Low
levels of expression of XPF correlate with better response to
induction chemoradiotherapy, while high levels of XPF expression
are associated with a worse response. Furthermore, pMK2, a
kinase that has been reported to be critical for post-transcriptional
regulation of gene expression as part of DNA damage response
[27], is significantly associated with overall survival after induction
plus chemoradiation therapy. Our results indicate that the analysis




Biopsy specimens (formalin-fixed, paraffin embedded tumor
samples) from 37 patients with stage IV locoregionally-advanced
HNSCC treated at the University of Chicago were evaluated from
whole sections. The HNSCC patient biopsies had been obtained
from a primary excision or biopsy prior to therapy. Written
informed consent was obtained from all donors or the next of kin
for the use of these samples in research approved under University
of Chicago IRB protocol 8980 and 15410A. All patients had been
treated with induction chemotherapy consisting of two cycles of
paclitaxel and carboplatin for a total of eight weeks. We
subsequently performed an interim assessment, followed by
paclitaxel, 5-fluorouracil, hydroxyurea and radiotherapy-based
regimens (FHX) based chemoradiotherapy and finally we evalu-
ated for response [28,29]. We analyzed the patient samples
regarding their HPV-status by staining for p16 (Santa Cruz JC-8).
Treatment evaluation
Response evaluation was performed in the interval between
induction chemotherapy and consecutive chemoradiotherapy by
CT scan and/or clinical examination by an ENT specialist and
best response was assessed. Response criteria were defined as
complete response (CR) [14], progressive response (PR) and stable
disease (SD) based on RECIST criteria [6,30].
Cell lines
The simian virus 40-transformed fibroblasts GM08437
(XPF2/2, Coriell Institute) cells and HeLa cells were grown in
Dulbecco’s modified Eagle’s medium supplemented with 10%
heat-inactivated fetal calf serum (FCS) in a humidified 5% CO2
incubator at 37uC.
Immunohistochemistry (IHC)
The whole sections of the samples were stained by IHC using
antibodies against XPF (SPM228)/ERCC1 (8F1) (AbCam),
FANCD2 (Santa Cruz), PAR, cH2AX (Millipore), MLH1
(AbSerotec) and phospho-MAPKAP Kinase2 (pMK2) (Cell
Signaling Technology). Tissue sections were deparaffinized/
rehydrated using standard techniques. Heat-induced epitope
retrieval was performed and the tissues were stained with
antibodies overnight at 4uC. Primary antibodies were omitted
for negative controls. Hematoxylin was used as nuclear counter-
stain. Two-fold antibody dilution ranges were established, and
antigen retrieval conditions were set such that antibody was in
excess and discriminated between control cancer tissues and
between low and high expression levels. Renaissance TSATM
(Tyramide Signal Amplification) Biotin System (Perkin Elmer) was
used for detection of XPF and FANCD2. Super Sensitive TM
IHC Detection System (BioGenex) was used for detection of PAR,
PARP1, MLH1, pMK2, cH2AX and ERCC1.
IHC Scoring
The IHC stained tissues on the slides were scanned into a digital
pathology platform (Aperio). Quality of staining pattern was
pathology reviewed. Intensity of nuclear staining, and/or locali-
zation of the marker into both nuclear and cytoplasmic
compartments was determined. Three tumor regions of interest
in a whole section were selected by pathologists in order to
minimize the effects of IHC staining variation. Scanned slides
were then evaluated by pathologists and machine-based digital
image analysis (Aperio). The percentage (0–100%) of tumor cells
with positive staining Quantity (Q) and intensity (I) for each
marker were independently scored by two trained pathologists
(VVB, SF), who were blinded from clinical history. A nuclear score
was reported for XPF, ERCC1, FANCD2, MLH1, PARP1, PAR
and cH2AX. The nuclear and cytoplasmic compartments were
scored separately for pMK2. Staining quantity (Q) was scored 0 to
4: no nuclear staining = 0; 1–9% of cells with nuclear stain = 1;
10–39% = 2; 40–69% = 3; and 70–100% = 4. Staining intensity (I)
was classified from 0 to 3, with 0 = negative, 1+= weak, 2+
= intermediate, 3+= strong. Final scores were obtained by
multiplying the quantity and staining intensity scores (IxQ) [31].
Machine-based image analyses were established based on modified
macros of the Aperio IHC nuclear algorithm to score the
intensity/quantity of positive tumor nuclei. Marker outputs in 0,
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1+, 2+, and 3+ bins were combined in a weighting algorithm to
create a relative intensity score (H-score) from 0–300 [32].
Immunoblotting
Immunoblotting for XPF, ERCC1, and b-Actin was done using
standard methodology as previously described [33–37]. Antibodies
used for immunoblotting were anti-XPF (SPM228, AbCam), anti-
ERCC1 (8F1, AbCam/Santa Cruz), and anti-b-Actin (H-170,
Santa Cruz). Nine head and neck cancer cell lines (SCC58,
SCC61, SCC35, SCC28, SQ20B, SCC9, HN5, SCC68, SCC25),
kindly provided by Dr. Ralph Weichselbaum and Dr. Mark
Lingen, were used.
Statistical Analysis
Biomarker scoring was correlated with clinical data to assess for
correlation with outcome. A set of optimal threshold marker values
was determined by univariate analysis for each marker that yielded
the highest discrimination to separate Complete response (CR),
Partial Response (PR), Stable Disease (SD) groups for induction
chemotherapy and overall survival. Multivariate analysis was not
feasible due to the small sample number. Univariate Cox
proportional hazards models were constructed for each of the
markers (single marker models) to examine their potential
predictive powers. Discriminant and partition analysis was also
conducted to maximally separate the dataset samples into groups.
Statistical outputs for p-value (Positive predictive value),
Apparent Error Rate (AER), Receiver Operator Characteristics
(ROC) and Area Under Curve (AUC). ROC is a graphical plot of
the sensitivity vs. (1-specificity) for a binary classifier system as its
discrimination of true positives, in this case, it is 1-specificity
(fraction of CR/PR called SD/PD) versus sensitivity (fraction of
SD/PD called SD/PD). AUC is a measure of how well two classes
of data separate under a testing scheme. Sensitivity, Specificity,
Positive Predictive Power, Negative Predictive Power, Relative
Risk (RR) and Odds Ratio were computed in the alternative
models.
To assess the association of the biomarker scores to overall
patient survival, thresholds for each biomarker were determined,
which separated patients into two groups. These thresholds were
selected by choosing the biomarker value that generated the
minimum survival curve p-value when patients with scores above
the threshold were compared to patients below the threshold.
Thresholds that created a minimum group size of less than 10% of
all samples were not considered reliable and excluded from
analysis.
Survival curves for the low- and high-risk groups were
compared using Kaplan-Meier models and the p-value reported.
Additionally, the AER, AUC, ROC curve, sensitivity, specificity,
positive predictive value, negative predictive value, and relative
risk are reported.
Results
Significant variations of DNA repair proteins expression
in multiple DNA repair pathways in head and neck cancer
DNA repair pathways are important for the cellular response to
chemotherapy and radiation. Eight selected DNA repair proteins
in five major DNA repair pathways were evaluated by IHC in a
cohort of 37 patients; an IHC staining example for each biomarker
is shown in Figure 1A. Pathologists’ scores and machine-based
assessment of IHC staining intensities in annotated tumor zones
were used to evaluate protein expression differences among patient
samples. Expression of DNA repair proteins varies between tumor
specimens as shown graphically in the patient distribution for the
markers (Figure 1B). Subcellular localization of pMK2 varies
between nuclear only, or nuclear + cytoplasmic localization
depending on the patient tumor. Several biomarkers such as
FANCD2 and cH2AX proteins have a distinct pattern in the
nucleus indicative of activation of the FA/Homologous recombi-
nation (HR) or DNA Damage Response (DDR) pathway
(Figure 1A) in these HNSCC tumors. Biomarkers in different
Figure 1. Immunohistochemistry (IHC) staining pattern of the DNA repair biomarkers. A. The FFPE whole sections from 37 HNSCC patient
samples were stained by IHC using the antibodies against DNA repair biomarkers (XPF, ERCC1, FANCD2, MLH1, pMK2, PAR, PARP1) according to the
protocol described in Materials and Methods. The stained tissue on the slide was scanned into a digital pathology platform (Aperio) and images were
viewed digitally, magnification 10X. As noted, subcellular localization of pMK2 is in either Nuclear (N), or Nuclear (N) + Cytoplasmic (C), staining
patterns of pMK2 in these cancer tissues is shown as indicated, magnification 20X. Nuclear foci in head neck cancer cells were shown for cH2AX and
FANCD2 in the lower panel as indicated, magnification 40X. B. Examples of varying biomarker expression in head and neck cancer tissue specimens
stained with XPF, FANCD2, MLH1 are shown. Patient distribution of XPF, FANCD2, MLH1 scores are plotted. C. Differences in the staining intensity and
distribution of XPF (NER), MLH1 (MMR), PAR (BER), FANCD2 (FA/HR), pMK2 and cH2AX (DDR) in parabasal (pb) and nonparabasal (non-pb) layer cells
from specimens of one representative HNSCC patient were shown as indicated.
doi:10.1371/journal.pone.0102112.g001
Figure 2. Association of XPF scoring by pathologist scores
versus machine assisted image analysis and quantitation.
Comparisons are made between alternative scoring strategies for
immunohistochemistry with the XPF for each head and neck cancer
patient. Machine assisted scoring for XPF was determined based on
percentage of nuclei with 1+ (weak), 2+ (medium), 3+ (high) intensity
Pathologist scores were Intensity (I). Correlation plots as shown are
computed for similarity with an R-value of 0.79.
doi:10.1371/journal.pone.0102112.g002
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DNA repair pathways such as XPF (NER), MLH1 (MMR), PAR
(BER), FANCD2 (FA/HR), pMK2 and cH2AX (DDR) were
found to have differences in the nuclear or cytoplasmic staining
intensity and distribution between parabasal (pb) and non-
parabasal (non-pb) layer cells for certain specimens, suggestive of
a variable expression of these DNA repair biomarkers (Figure 1C).
An example shown here is the nuclear staining pattern of NER
biomarker XPF in two representative cancers by IHC. Low or
negative intensity of XPF nuclear staining indicates that NER
pathway is off, and high intensity of XPF staining indicates that
NER pathway is on (Figure 2). To test the correlations between
pathologist scores, machine-guided and image analysis, we
compared IHC stained XPF, which were analyzed by two
pathologists, who were blinded to tumor samples, and machine-
based algorithm in this study (Figure 2) with R2 value of 0.79.
Highly variable XPF expression in head and neck cancer
In our study, we determined specificity of the XPF (SPM228)
and ERCC1 (8F1) antibodies by IHC using formalin fixed,
paraffin-embedded blocks of HeLa (positive control) and XPF
deficient cell pellets. Other XPF and ERCC1 antibodies were
evaluated (data not shown/proprietary). SPM228 was chosen due
to high degree of specificity, and 8F1 chosen as it is the most
widely used ERCC1 antibody. Our result showed that specific
nuclear staining by a monoclonal antibody against XPF (SPM228)
was detected in HeLa cells but not in XPF deficient cells, in
contrast, nuclear staining by the ERCC1 8F1 antibody was found
in both HeLa and XPF deficient cells, indicating that this SPM228
antibody is XPF specific and suitable for detection of XPF by IHC,
and ERCC1 8F1 recognizes additional non-specific nuclear
proteins and is unable to specifically detect ERCC1 in specimens
(Figure 3A).
We evaluated XPF expression in both, p16(+) and p16(2)
samples and did not detect a significant difference (178 versus 165,
NS).
Figure 3. Immunohistochemistry (IHC) staining pattern of XPF and ERCC1 by using anti-XPF (SPM228) and ERCC1 (8F1) antibodies
and XPF expression in HNSCC cell lines. A. FFPE blocks of HeLa and GM08437 (XPF deficient cell) pellets were used as negative and positive
controls, XPF (SPM228) and ERCC1 (8F1) antibodies were then applied to the sections by immunohistochemistry according to the IHC method for
tumor, and nuclear staining patterns of XPF and ERCC1 were shown. B. Nine head and neck cancer cell lines were analyzed by immunoblotting for
expression of XPF. XPF and XPF breakdown proteins were detected by an anti-XPF monoclonal antibody (SPM228) with cell lines 5 and 6 showing low
expression. b-Actin (Santa Cruz) was used as a protein loading control. The names of the cell lines are listed.
doi:10.1371/journal.pone.0102112.g003
Figure 4. Univariate analysis of XPF biomarker scores shows
improved response prediction to induction chemotherapy in
head and neck cancer. The chart shows that univariate analysis of
the XPF biomarker scores relative to the discrimination between
Responder subgroups. The primary outcome measurement was
response to induction chemotherapy.
doi:10.1371/journal.pone.0102112.g004
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We then measured the level of XPF expression in lysates of nine
HNSCC cell lines by immunoblot. Two bands of XPF at 110 kD
and 75 kD were found consistently, with the 75 kD band
recognizing full length XPF and the other band representing a
cleavage product of XPF (XPF breakdown) (Figure 3B). We also
found that levels of expression of XPF dramatically vary among
nine HNSCC cell lines (Figure 3B). A wide dynamic range of XPF
expression in the cohort in our study is also shown in a patient
distribution plot (Figure 1B). Taken together, our results demon-
strate that levels of XPF expression detected by the SPM228
antibody vary significantly in head and neck cell lines and patient
specimens, and that the monoclonal antibody SPM228 can be
used to specifically detect XPF expression by Western blot and
IHC.
XPF is associated with response to induction
chemotherapy for head and neck cancer patients
Eight DNA repair biomarkers stained on 37 patient specimens
by IHC were analyzed for their ability to predict response to
induction chemotherapy. Of the 37 HNC patients treated with
induction chemotherapy in the study, complete response (CR) [14]
was observed in 11 patients (29.7%), 19 patients (51.4%) obtained
a partial response (PR), and seven patients (18.9%) had a stable
disease (SD). We found that low levels of XPF expression in HNC
patients were significantly associated with better response to
induction chemotherapy (p = 0.02) (Figure 4). Moreover, all of
seven patients who had SD had high levels of XPF expression
(Figure 3, Table 1). In contrast, ERCC1 detected by the
commonly used antibody (clone 8F1) in our cohort set did not
correlate with response, and other markers such as PARP1, PAR,
MLH1, pMK2, cH2AX, FANCD2, also failed to correlate
(Table 1). Our results suggest that XPF is the preferred NER
biomarker to predict response to induction chemotherapy in
HNSCC patients.
pMK2 correlates with overall survival to chemoradiation
therapy
We then evaluated association of the DNA repair biomarkers to
overall survival for this cohort of patients. pMK2 did not correlate
with response to induction chemotherapy (Table 1), but it
correlated strongly with overall survival: low pMK2 expression
was associated with better overall survival (p = 0.01) (Figure 5);
pMK2 differentiated a subgroup with improved survival poten-
tially related to chemoradiation therapy, suggesting that pMK2
may relate to chemoradiation therapy. In contrast, XPF was found
not to correlate with overall survival (p = 0.08). For several other
markers in DNA repair such as PARP1, PAR, MLH1, cH2AX,
ERCC1, FANCD2, the same analysis failed to reach statistical
significance (Table 2). Further study of pMK2 is needed.
Discussion
Chemotherapy induces DNA-damage in tumor cells. Therefore
the ability to repair such damage using specific DNA repair
Table 1. List of DNA repair proteins in univariate analysis of the correlation with response to induction chemotherapy.
Biomarker ROC plot/AUC value % Correct Responders at 100% SD/PD Correct P value (CR/PR vs SD)
XPF 0.783 60 0.0193
ERCC1 0.569 7 0.41
pMK2 0.707 47 0.266
MLH 1 0.545 23 0.616
PARP 1 0.571 20 0.918
PAR 0.509 17 0.872
FANCD2 0.571 13 0.952
c-H2AX 0.519 N/A 0.629
Higher AUC value means better correlations with response to induction chemotherapy. P values of CR/PR versus SD are shown.
doi:10.1371/journal.pone.0102112.t001
Figure 5. Correlation of expression levels of pMK2 with overall
survival. Overall survival estimated by best response to induction
chemotherapy using Kaplan-Meier survival curves based on the nuclear
staining intensity and quantitation of pMK2 determined by patholo-
gists’ scores as NQ (Nuclear Quantity).
doi:10.1371/journal.pone.0102112.g005
Table 2. List of p values of DNA repair proteins in univariate
analysis of the correlation with overall survival.
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pathways is likely predictive of drug sensitivity/resistance, and
treatment outcome. Thus, diagnostic DNA repair biomarkers hold
potential to significantly change diagnostic strategies and affect
therapeutic decision-making and treatment planning for patients
with head and neck cancer. In our study, we evaluated eight DNA
repair biomarkers in five different DNA repair pathways by
immunohistochemistry in locoregionally-advanced head and neck
cancer. Significant variations in multiple DNA repair pathways
were observed in HNSCC tumors suggesting that clinical decisions
may be influenced by a DNA repair biomarker profile (Figures 1,
2). Among all of the DNA repair biomarkers that we analyzed,
XPF was the single best marker to predict response to induction
chemotherapy by univariate analysis; low levels of expression of
XPF in head and neck cancer patients were associated with better
response to induction chemotherapy. High levels of XPF
expression in head and neck patients correlated with worse
response to platinum based chemotherapy consistent with prior
reports [38]. By contrast ERCC1 (8F1), detected by the commonly
used antibody (clone 8F1), in our cohort set did not correlate with
response, which may relate to its poorer specificity (Figures 3 and
4, Table 1). ERCC1 (8F1) performance was not adequate in our
study and we hypothesize that the decreased specificity can be
compensated by larger sample sizes as seen in other studies [18–
20]. Furthermore it is possible that the ERCC1 8F1 measures
something different than ERCC1, which correlates with survival.
While patient response to induction chemotherapy is a potential
predictor of good overall outcome as reported by several groups
[4,5,39–41], overall survival remains clinically most meaningful.
pMK2 was found to correlate significantly (p = 0.01) with overall
survival. Since pMK2 does not appear to relate to induction
response it may be a potential marker of treatment success for
concurrent chemoradiation (Figure 5, Table 2) consistent with
preclinical data [42].
Given the heterogeneity of head and neck cancer, and the
intricately connected network of six major DNA repair pathways,
it is unreasonable to anticipate that meaningful diagnostic testing
can rely on a single, specific marker. As our study suggests,
markers for induction and chemoradiation are likely different.
Furthermore, compensation of DNA repair in the absence of one
repair pathway by another pathway suggests the possibility that
multiple markers may be necessary to optimally assess responsive-
ness. Such a DNA repair response signature will have to be
evaluated by our group, using a larger cohort and may allow
improved assessment of HNC heterogeneity and complexities of
DNA repair networks.
In conclusion, our study provides an established method to
measure DNA repair biomarkers and other biomarkers using
quantitative immunohistochemistry to identify and evaluate
functional changes to DNA repair and damage signaling pathways
as a valuable tool for personalized diagnostics. Our results indicate
usefulness of XPF as a biomarker to predict which patients benefit
from which treatments with induction chemotherapy. Specifically
XPF proved superior to ERCC1 (8F1) testing. XPF may also have
value to predict overall treatment success, which potentially relates
to its role for prediction of induction response [25]. Furthermore,
our results suggest that pMK2 is a potential marker for
chemoradiation as it did not correlate with induction response,
but did correlate strongly with overall survival. Further validation
of these markers in a larger cohort of advanced head and neck
cancer patients is imperative and our observations are largely
hypothesis-forming at this point, but are consistent with other
literature [38]. Ultimately, multiple markers may be necessary to
optimally assess tumor specimens, and provide the most informa-
tion to treating physicians.
Acknowledgments
Flight Attendant Medical Research Institute (FAMRI) YCSA (TYS),
Cancer Research Foundation YIA (TYS), ASCO translational professor-
ship award (EEV). We would like to thank Dr. Brian E. Ward for his
continued support.
Author Contributions
Conceived and designed the experiments: EEV TS XW RRW DW.
Performed the experiments: TS XW VVB K. Sprott SF EO MWL.
Analyzed the data: MWL DTW DAF TS JH. Contributed reagents/
materials/analysis tools: RRW MWL EEV EEC XW K. Stenson. Wrote
the paper: TS JH.
References
1. Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, et al. (2010) Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:
2893–2917. Available: http://www.ncbi.nlm.nih.gov/pubmed/21351269. Ac-
cessed 2012 Oct 4.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (n.d.) Cancer statistics, 2009. CA
Cancer J Clin 59: 225–249. Available: http://www.ncbi.nlm.nih.gov/pubmed/
19474385. Accessed 2012 Oct 25.
3. Seiwert TY, Salama JK, Vokes EE (2007) The chemoradiation paradigm in
head and neck cancer. Nat Clin Pract Oncol 4: 156–171. Available: http://
www.ncbi.nlm.nih.gov/pubmed/17327856. Accessed 2012 Oct 25.
4. Salama JK, Seiwert TY, Vokes EE (2007) Chemoradiotherapy for locally
advanced head and neck cancer. J Clin Oncol 25: 4118–4126. Available: http://
www.ncbi.nlm.nih.gov/pubmed/17827462. Accessed 2012 Oct 25.
5. Salama JK, Stenson KM, Kistner EO, Mittal BB, Argiris A, et al. (2008)
Induction chemotherapy and concurrent chemoradiotherapy for locoregionally
advanced head and neck cancer: a multi-institutional phase II trial investigating
three radiotherapy dose levels. Ann Oncol 19: 1787–1794. Available: http://
www.ncbi.nlm.nih.gov/pubmed/18539617. Accessed 2012 Oct 25.
6. Vokes EE, Kies MS, Haraf DJ, Stenson K, List M, et al. (2000) Concomitant
chemoradiotherapy as primary therapy for locoregionally advanced head and
neck cancer. J Clin Oncol 18: 1652–1661. Available: http://www.ncbi.nlm.nih.
gov/pubmed/10764425. Accessed 2012 Oct 25.
7. Fakhry C, Westra WH, Li S, Cmelak A, Ridge JA, et al. (2008) Improved
survival of patients with human papillomavirus-positive head and neck
squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst
100: 261–269. Available: http://www.ncbi.nlm.nih.gov/pubmed/18270337.
Accessed 2012 Oct 25.
8. Haddad R, O’Neill A, Rabinowits G, Tishler R, Khuri F, et al. (2013) Induction
chemotherapy followed by concurrent chemoradiotherapy (sequential chemor-
adiotherapy) versus concurrent chemoradiotherapy alone in locally advanced
head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol
14: 257–264. Available: http://www.ncbi.nlm.nih.gov/pubmed/23414589.
Accessed 2012 Oct 25.
9. Pignon JP, Bourhis J, Domenge C, Designe´ L (2000) Chemotherapy added to
locoregional treatment for head and neck squamous-cell carcinoma: three meta-
analyses of updated individual data. MACH-NC Collaborative Group. Meta-
Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355: 949–955.
Available: http://www.ncbi.nlm.nih.gov/pubmed/10768432. Accessed 2012
Oct 25.
10. Alter BP, Joenje H, Oostra AB, Pals G (2005) Fanconi anemia: adult head and
neck cancer and hematopoietic mosaicism. Arch Otolaryngol Head Neck Surg
131: 635–639. Available: http://www.ncbi.nlm.nih.gov/pubmed/16027289.
Accessed 2012 Oct 25.
11. Van Waes C (2005) Head and neck squamous cell carcinoma in patients with
Fanconi anemia. Arch Otolaryngol Head Neck Surg 131: 640–641.Available:
http://www.ncbi.nlm.nih.gov/pubmed/16027290. Accessed 2012 Oct 25.
12. Rosenberg PS, Socie´ G, Alter BP, Gluckman E (2005) Risk of head and neck
squamous cell cancer and death in patients with Fanconi anemia who did and
did not receive transplants. Blood 105: 67–73. Available: http://www.ncbi.nlm.
nih.gov/pubmed/15331448. Accessed 2012 Oct 25.
13. He Y, Chen Q, Li B (2008) ATM in oral carcinogenesis: association with
clinicopathological features. J Cancer Res Clin Oncol 134: 1013–1020.
Available: http://www.ncbi.nlm.nih.gov/pubmed/18288488. Accessed 2012
Oct 25.
14. Van Zeeburg HJT, Snijders PJF, Pals G, Hermsen MAJA, Rooimans MA, et al.
(2005) Generation and molecular characterization of head and neck squamous
cell lines of fanconi anemia patients. Cancer Res 65: 1271–1276. Available:
http://www.ncbi.nlm.nih.gov/pubmed/15735012. Accessed 2012 Oct 25.
DNA Repair Biomarkers in HNC
PLOS ONE | www.plosone.org 7 July 2014 | Volume 9 | Issue 7 | e102112
15. Berkower AS, Biller HF (1988) Head and neck cancer associated with Bloom’s
syndrome. Laryngoscope 98: 746–748. Available: http://www.ncbi.nlm.nih.
gov/pubmed/3290604. Accessed 2012 Oct 25.
16. Iguchi H, Takayama M, Kusuki M, Sunami K, Nakamura A, et al. (2004) A
possible case of Werner syndrome presenting with multiple cancers. Acta
Otolaryngol Suppl: 67–70. Available: http://www.ncbi.nlm.nih.gov/pubmed/
15513515. Accessed 2012 Oct 25.
17. Friedlander PL (2001) Genomic instability in head and neck cancer patients.
Head Neck 23: 683–691. Available: http://www.ncbi.nlm.nih.gov/pubmed/
11443752. Accessed 2012 Oct 25.
18. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre´ F, et al. (2006) DNA
repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant
chemotherapy. N Engl J Med 355: 983–991. Available: http://www.ncbi.nlm.
nih.gov/pubmed/16957145. Accessed 2012 Oct 25.
19. Jun HJ, Ahn MJ, Kim HS, Yi SY, Han J, et al. (2008) ERCC1 expression as a
predictive marker of squamous cell carcinoma of the head and neck treated with
cisplatin-based concurrent chemoradiation. Br J Cancer 99: 167–172. Available:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 2453006&tool =
pmcentrez&rendertype = abstract. Accessed 2012 Oct 25.
20. Kang S, Ju W, Kim JW, Park NH, Song YS, et al. (2006) Association between
excision repair cross-complementation group 1 polymorphism and clinical
outcome of platinum-based chemotherapy in patients with epithelial ovarian
cancer. Exp Mol Med 38: 320–324. Available: http://www.ncbi.nlm.nih.gov/
pubmed/16819291. Accessed 2012 Oct 25.
21. McNeil EM, Melton DW (2012) DNA repair endonuclease ERCC1-XPF as a
novel therapeutic target to overcome chemoresistance in cancer therapy. Nucleic
Acids Res: 1–15. Available: http://www.ncbi.nlm.nih.gov/pubmed/22941649.
Accessed 2012 Oct 25.
22. Biggerstaff M, Szymkowski DE, Wood RD (1993) Co-correction of the ERCC1,
ERCC4 and xeroderma pigmentosum group F DNA repair defects in vitro.
EMBO J 12: 3685–3692. Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid = 413645&tool = pmcentrez&rendertype = abstract. Ac-
cessed 2012 Oct 25.
23. Niedernhofer LJ, Bhagwat N, Wood RD (2007) ERCC1 and non-small-cell lung
cancer. N Engl J Med 356: 2538–40; author reply 2540–1. Available: http://
www.ncbi.nlm.nih.gov/pubmed/17568038. Accessed 2012 Oct 25.
24. Bhagwat NR, Roginskaya VY, Acquafondata MB, Dhir R, Wood RD, et al.
(2009) Immunodetection of DNA repair endonuclease ERCC1-XPF in human
tissue. Cancer Res 69: 6831–6838. Available: http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid = 2739111&tool = pmcentrez&rendertype = abstract.
Accessed 2012 Oct 25.
25. Ko¨berle B, Ditz C, Kausch I, Wollenberg B, Ferris RL, et al. (2010) Metastases
of squamous cell carcinoma of the head and neck show increased levels of
nucleotide excision repair protein XPF in vivo that correlate with increased
chemoresistance ex vivo: 1277–1284. doi:10.3892/ijo
26. Chiu T-J, Chen C-H, Chien C-Y, Li S-H, Tsai H-T, et al. (2011) High ERCC1
expression predicts cisplatin-based chemotherapy resistance and poor outcome
in unresectable squamous cell carcinoma of head and neck in a betel-chewing
area. J Transl Med 9: 31. Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid = 3072326&tool = pmcentrez&rendertype = abstract. Ac-
cessed 2012 Oct 25.
27. Vugt MATM Van, Wang X, Linding R, Ong S, Weaver D, et al. (2011) NIH
Public Access. 40: 34–49. doi:10.1016/j.molcel.2010.09.018.DNA
28. Haraf DJ, Rosen FR, Stenson K, Argiris A, Mittal BB, et al. (2003) Induction
chemotherapy followed by concomitant TFHX chemoradiotherapy with
reduced dose radiation in advanced head and neck cancer. Clin Cancer Res
9: 5936–5943. Available: http://www.ncbi.nlm.nih.gov/pubmed/14676118.
Accessed 2012 Oct 25.
29. Vokes EE, Stenson K, Rosen FR, Kies MS, Rademaker AW, et al. (2003)
Weekly carboplatin and paclitaxel followed by concomitant paclitaxel,
fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserv-
ing therapy for advanced head and neck cancer. J Clin Oncol 21: 320–326.
Available: http://www.ncbi.nlm.nih.gov/pubmed/12525525. Accessed 2012
Oct 25.
30. Michiels S, Le Maıˆtre A, Buyse M, Burzykowski T, Maillard E, et al. (2009)
Surrogate endpoints for overall survival in locally advanced head and neck
cancer: meta-analyses of individual patient data. Lancet Oncol 10: 341–350.
Available: http://www.ncbi.nlm.nih.gov/pubmed/19246242. Accessed 2012
Oct 25.
31. Nanni S, Benvenuti V, Grasselli A, Priolo C, Aiello A, et al. (2009) Endothelial
NOS, estrogen receptor beta, and HIFs cooperate in the activation of a
prognostic transcriptional pattern in aggressive human prostate cancer. J Clin
Invest 119: 1093–1108. Available: http://www.pubmedcentral.nih.gov/
articlerender.fcgi?artid = 2673846&tool = pmcentrez&rendertype = abstract. Ac-
cessed 2012 Oct 25.
32. Alexander BM, Sprott K, Farrow DA, Wang X, D’Andrea AD, et al. (2010)
DNA repair protein biomarkers associated with time to recurrence in triple-
negative breast cancer. Clin Cancer Res 16: 5796–5804. Available: http://www.
ncbi.nlm.nih.gov/pubmed/21138871. Accessed 2012 Oct 25.
33. Ma PC, Kijima T, Maulik G, Fox EA, Sattler M, et al. (2003) c-MET mutational
analysis in small cell lung cancer: novel juxtamembrane domain mutations
regulating cytoskeletal functions. Cancer Res 63: 6272–6281. Available: http://
www.ncbi.nlm.nih.gov/pubmed/14559814. Accessed 2012 Oct 25.
34. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, et al.
(2006) Functional analysis of c-Met/hepatocyte growth factor pathway in
malignant pleural mesothelioma. Cancer Res 66: 352–361. Available: http://
www.ncbi.nlm.nih.gov/pubmed/16397249. Accessed 2012 Oct 25.
35. Jagadeeswaran R, Surawska H, Krishnaswamy S, Janamanchi V, Mackinnon
AC, et al. (2008) Paxillin is a target for somatic mutations in lung cancer:
implications for cell growth and invasion. Cancer Res 68: 132–142. Available:
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 2767335&tool =
pmcentrez&rendertype = abstract. Accessed 2012 Oct 25.
36. Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, et al.
(2005) Functional expression and mutations of c-Met and its therapeutic
inhibition with SU11274 and small interfering RNA in non-small cell lung
cancer. Cancer Res 65: 1479–1488. Available: http://www.ncbi.nlm.nih.gov/
pubmed/15735036. Accessed 2012 Oct 25.
37. Seiwert TY, Jagadeeswaran R, Faoro L, Janamanchi V, Nallasura V, et al.
(2009) The MET receptor tyrosine kinase is a potential novel therapeutic target
for head and neck squamous cell carcinoma. Cancer Res 69: 3021–3031.
Available: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid = 2871252
&tool = pmcentrez&rendertype = abstract. Accessed 2012 Oct 25.
38. Vaezi A, Wang X, Buch S, Gooding W, Wang L, et al. (2011) XPF expression
correlates with clinical outcome in squamous cell carcinoma of the head and neck.
Clin Cancer Res 17: 5513–5522. Available: http://www.pubmedcentral.nih.
gov/articlerender.fcgi?artid = 3156890&tool = pmcentrez&rendertype = abstract.
Accessed 2014 March 12.
39. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, et al. (2006) Rate of
pathologic complete responses to docetaxel, cisplatin, and fluorouracil induction
chemotherapy in patients with squamous cell carcinoma of the head and neck.
Arch Otolaryngol Head Neck Surg 132: 678–681. Available: http://www.ncbi.
nlm.nih.gov/pubmed/16785415. Accessed 2012 Oct 25.
40. Dietz A, Rudat V, Dreyhaupt J, Pritsch M, Hoppe F, et al. (2009) Induction
chemotherapy with paclitaxel and cisplatin followed by radiotherapy for larynx
organ preservation in advanced laryngeal and hypopharyngeal cancer offers
moderate late toxicity outcome (DeLOS-I-trial). Eur Arch Otorhinolaryngol
266: 1291–1300. Available: http://www.ncbi.nlm.nih.gov/pubmed/18972123.
Accessed 2012 Oct 25.
41. Pointreau Y, Garaud P, Chapet S, Sire C, Tuchais C, et al. (2009) Randomized
trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without
docetaxel for larynx preservation. J Natl Cancer Inst 101: 498–506. Available:
http://www.ncbi.nlm.nih.gov/pubmed/19318632. Accessed 2012 Oct 25.
42. Reinhardt HC, Hasskamp P, Schmedding I, Morandell S, van Vugt MATM, et
al. (2010) DNA damage activates a spatially distinct late cytoplasmic cell-cycle
checkpoint network controlled by MK2-mediated RNA stabilization. Mol Cell
40: 34–49. Available: http://www.pubmedcentral.nih.gov/articlerender.
fcgi?artid = 3030122&tool = pmcentrez&rendertype = abstract. Accessed 2014
Feb 20.
DNA Repair Biomarkers in HNC
PLOS ONE | www.plosone.org 8 July 2014 | Volume 9 | Issue 7 | e102112
